Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 7.5% – Here’s What Happened

Pulse Biosciences, Inc (NASDAQ:PLSE)’s stock price traded up 7.5% during trading on Wednesday . The company traded as high as $25.45 and last traded at $25.7250. 149,008 shares traded hands during mid-day trading, a decline of 56% from the average session volume of 334,937 shares. The stock had previously closed at $23.92.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PLSE. Mizuho set a $30.00 target price on Pulse Biosciences in a report on Friday, February 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Pulse Biosciences presently has an average rating of “Hold” and a consensus price target of $26.00.

Pulse Biosciences Price Performance

The company’s fifty day moving average price is $14.73 and its 200-day moving average price is $15.59. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -22.35 and a beta of 1.77.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. AlphaQuest LLC boosted its holdings in shares of Pulse Biosciences by 184.5% in the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock valued at $134,000 after acquiring an additional 5,748 shares during the last quarter. Inspire Investing LLC grew its holdings in Pulse Biosciences by 19.7% during the second quarter. Inspire Investing LLC now owns 25,891 shares of the company’s stock worth $391,000 after acquiring an additional 4,267 shares during the period. Westside Investment Management Inc. raised its position in Pulse Biosciences by 10.5% during the second quarter. Westside Investment Management Inc. now owns 64,290 shares of the company’s stock valued at $970,000 after acquiring an additional 6,135 shares in the last quarter. Brevan Howard Capital Management LP acquired a new position in Pulse Biosciences in the second quarter valued at approximately $215,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Pulse Biosciences in the second quarter valued at approximately $158,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.